Pa­tient death leads Seat­tle Chil­dren’s to pause study of 2sev­en­ty bio’s CAR-T cell ther­a­py 

2sev­en­ty bio said its part­ner Seat­tle Chil­dren’s has paused a Phase I study of the biotech’s CAR-T cell ther­a­py fol­low­ing a pa­tient death.

The ther­a­py, dubbed SC-DAR­IC33, is be­ing in­ves­ti­gat­ed in pe­di­atric and young adult pa­tients with acute myeloid leukemia. The first pa­tient to re­ceive the ther­a­py at the sec­ond dose lev­el died.

“The root cause of this SAE and its po­ten­tial re­la­tion­ship to the study drug is cur­rent­ly un­der in­ves­ti­ga­tion,” the Cam­bridge, MA-based biotech said in a Wednes­day morn­ing state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER